Merz Pharmaceuticals GmbH, Eckenheimer Landstrasse 100, 60318 Frankfurt am Main, Germany.
Bioorg Med Chem Lett. 2013 Aug 15;23(16):4493-500. doi: 10.1016/j.bmcl.2013.06.049. Epub 2013 Jun 25.
A virtual screening approach using various in silico methodologies led to the discovery of 2-(m-tolylamino)-7,8-dihydroquinazolin-5(6H)-one (1) as a moderately active negative allosteric modulator (NAM) of the metabotropic glutamate receptor subtype 5 (mGluR5) showing high selectivity against the subtype mGluR1. Modifications of the parent compound by rational design yielded a series of highly potent derivatives which will serve as valuable starting points for further hit-to-lead optimization efforts toward a suitable drug candidate for the treatment of L-DOPA induced dyskinesia.
一种使用各种计算机模拟方法的虚拟筛选方法导致发现了 2-(m-甲苯氨基)-7,8-二氢喹唑啉-5(6H)-酮(1),它是代谢型谷氨酸受体亚型 5(mGluR5)的中等活性负变构调节剂(NAM),对亚型 mGluR1 具有高选择性。通过合理设计对母体化合物进行修饰,得到了一系列高活性的衍生物,它们将作为有价值的起点,进一步进行从苗头化合物到先导化合物的优化,以开发出适合治疗 L-DOPA 诱导运动障碍的候选药物。